MedTrace Logo

Intestinal Flora and Major Depressive Disorders

NCT04347577 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-04-17

No results posted yet for this study

Summary

As an important micro-ecological factor in human body, intestinal flora is closely related to the occurrence and development of major depressive disorder. The purpose of our study is to investigate a microbiome probe of depression. This study is a 6-months open trial that will enroll approximately 30 patients in major depressive disorders and 10 age- and sex-matched healthy controls. We will comparing gut bacteria community structures of pre- treatment, those of 1 month and 6 months after treatment to remission. With the microbiome change in a preliminary analysis of pre-and post-treatment, we will reveal the diversity before and after the depression treatment.

Conditions

Interventions

DRUG

duloxetine

open-label study

Sponsors & Collaborators

  • Capital Medical University

    collaborator OTHER

  • Beijing Chao Yang Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-10
Primary Completion
2022-10-01
Completion
2023-04-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347577 on ClinicalTrials.gov